Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT02419469 · ClinicalTrials.gov registry record · Phase 2
Augmented Berlin-Frankfurt-Munster Therapy Plus Ofatumumab for Young Adults With Acute Lymphoblastic Leukemia or Lymphoblastic Lymphoma
A Phase 2 study, sponsored by M.D. Anderson Cancer Center.
- Terminated
- Registry status
- Phase 2
- Development phase
- 1
- Enrollment target
NCT02419469: Clinical Trial Phase 2 study, sponsored by M.D. Anderson Cancer Center.
NCT02419469 is a Phase 2 study that was terminated before completion, run by M.D. Anderson Cancer Center. The registered enrollment target is 1 participants. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT02419469, a Phase 2 study, was terminated before completion, sponsored by M.D. Anderson Cancer Center.
- TERMINATED
- Registry status
- Phase 2
- Development phase
- 1 participants
- Enrollment target
Study Summary
The goal of this clinical research study is to learn if a chemotherapy combination called augmented Berlin-Frankfurt-Munster (BFM), when also combined with ofatumumab or rituximab, can help to control precursor-B ALL or LL in patients who are 12-30 years of age. The safety of these drug combinations will also be studied. Augmented BFM is made up of daunorubicin, vincristine, prednisone, dexamethasone, PEG asparaginase, and methotrexate.
Interventions
- DRUG Vincristine
- DRUG Prednisone
- DRUG Cytarabine
- DRUG Daunorubicin
- DRUG PEG asparaginase
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 1 participants |
| Start Date | 2015-11-13 |
| Est. Completion | 2017-06-22 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT02419469
The ClinicalTrials.gov registry entry for NCT02419469 describes a study currently listed as terminated, categorized as Phase 2. The registered enrollment target is 1 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is M.D. Anderson Cancer Center, which has 2,692 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 5 interventions - of which Vincristine is the first listed.
NCT02419469 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT02419469 about?
NCT02419469 is a clinical study titled "Augmented Berlin-Frankfurt-Munster Therapy Plus Ofatumumab for Young Adults With Acute Lymphoblastic Leukemia or Lymphoblastic Lymphoma". The goal of this clinical research study is to learn if a chemotherapy combination called augmented Berlin-Frankfurt-Munster (BFM), when also combined with ofatumumab or rituximab, can help to control precursor-B ALL or LL in patients who are 12-30 years of age. The safety of these drug combinations...
What is the current status of trial NCT02419469?
This trial is currently terminated. It is a Phase 2 study. The enrollment target is 1 participants. The study started on 2015-11-13. Estimated completion is 2017-06-22.
What interventions are being tested in trial NCT02419469?
The interventions under investigation include: Vincristine (DRUG), Prednisone (DRUG), Cytarabine (DRUG), Daunorubicin (DRUG), PEG asparaginase (DRUG).
Who is sponsoring clinical trial NCT02419469?
This trial is sponsored by M.D. Anderson Cancer Center, which has 2,692 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, the data changelog, or report a data error.